Safety, efficacy, and translatability are the primary concerns at the preclinical stage of pharmaceutical research. Immortalized cell lines and animal models have often been used to predict the success of new drugs; however, the limitations of these methods are becoming more apparent as new modality therapeutics emerge. Primary cell derived organ on a chip devices are the solution.

Drug-drug interactions (DDIs) pose a significant threat to patient safety and drug development, leading to hospitalizations and trial setbacks. This post explores why traditional preclinical models often fail to predict these complex interactions, especially those with delayed or long-term effects, and hints at the need for more advanced in vitro systems capable of longitudinal studies.

The rise of next-generation therapeutics demands more sophisticated testing. Part 1 of our series explores why current preclinical models often fall short in evaluating these advanced therapies, highlighting the limitations of animal studies and traditional cell cultures. Discover the growing "translational gap" and the urgent need for innovative, human-relevant systems to bridge it. Stay tuned for Part 2, where we'll delve into a potential solution.